Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. GPCR
stocks logo

GPCR

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.381
+73.34%
--
--
-0.395
+46.14%
--
--
-0.409
+13.74%
Estimates Revision
The market is revising Downward the revenue expectations for Structure Therapeutics Inc. (GPCR) for FY2025, with the revenue forecasts being adjusted by -97.04% over the past three months. During the same period, the stock price has changed by 48.78%.
Revenue Estimates for FY2025
Revise Downward
down Image
-97.04%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-1.62%
In Past 3 Month
Stock Price
Go Up
up Image
+48.78%
In Past 3 Month
Wall Street analysts forecast GPCR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GPCR is 73.38 USD with a low forecast of 50.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast GPCR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GPCR is 73.38 USD with a low forecast of 50.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
0 Hold
0 Sell
Strong Buy
Current: 32.850
sliders
Low
50.00
Averages
73.38
High
100.00
Current: 32.850
sliders
Low
50.00
Averages
73.38
High
100.00
Citi
Buy
maintain
$60
2025-11-03
Reason
Citi
Price Target
$60
2025-11-03
maintain
Buy
Reason
Citi opened a "positive 90-day catalyst watch" on shares of Structure Therapeutics while keeping a Buy rating on the name with a $60 price target. Citi views Structure's risk/reward into the Phase 2b ACCESS and ACCESS II data for aleniglipron, expected by the end of 2025, as favorable.
Citizens JMP
NULL -> Outperform
maintain
$89 -> $87
2025-08-07
Reason
Citizens JMP
Price Target
$89 -> $87
2025-08-07
maintain
NULL -> Outperform
Reason
Citizens JMP lowered the firm's price target on Structure Therapeutics to $87 from $89 and keeps an Outperform rating on the shares following the Q2 report. The firm says the company will release the Phase 2b data for aleniglipron by the end of 2025.
Leerink
David Risinger
Outperform
to
NULL
downgrade
$60 -> $44
2025-08-07
Reason
Leerink
David Risinger
Price Target
$60 -> $44
2025-08-07
downgrade
Outperform
to
NULL
Reason
Leerink analyst David Risinger lowered the firm's price target on Structure Therapeutics to $44 from $60 and keeps an Outperform rating on the shares. The firm cites change to its terminal growth rate to reflect longer-term competition. Leerink notes that Structure reiterated that it continues to anticipate topline Phase 2b 36-week data from oral small molecule GLP-1 aleniglipron ACCESS and ACCESS II studies by year-end 2025. The company is also expanding aleniglipron's clinical development program to optimize competitive positioning and its future Phase 3 program.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$60 -> $75
2025-08-07
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$60 -> $75
2025-08-07
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Structure Therapeutics (GPCR) to $75 from $60 and keeps a Buy rating on the shares. The firm views Eli Lilly's (LLY) orforglipron data from the ATTAIN-1 study showing 12.4% body weight loss from the baseline as "encouraging" for Structure's aleniglipron. Given Lilly's data, aleniglipron "may emerge as a strong contender for best-in-class profile based on several differentiating factors," the analyst tells investors in a research note.
Guggenheim
Buy
downgrade
$92 -> $90
2025-08-07
Reason
Guggenheim
Price Target
$92 -> $90
2025-08-07
downgrade
Buy
Reason
Guggenheim lowered the firm's price target on Structure Therapeutics to $90 from $92 and keeps a Buy rating on the shares after the company reiterated that top-line data from the Phase 2b ACCESS and ACCESS II studies for oral small molecule GLP1RA aleniglipron are on track for concurrent year-end 2025 readouts. The firm continues to recommend that investors build a position in advance of the ACCESS/ACCESS II readouts given what it sees as "a mismatched valuation."
Clear Street
Kaveri Pohlman
Buy
initiated
$61
2025-07-30
Reason
Clear Street
Kaveri Pohlman
Price Target
$61
2025-07-30
initiated
Buy
Reason
Clear Street analyst Kaveri Pohlman initiated coverage of Structure Therapeutics with a Buy rating and $61 price target. The firm contends that oral formulations are poised to disrupt the diabesity market, offering efficacy and safety that rivals, if not surpasses, current standards, the analyst tells investors in a research note. Structure's lead asset, aleniglipron, is a scalable, small-molecule oral GLP-1 inhibitor that could deliver a game-changing proof of concens with Phase 2b data expected by 2025-end, and if results match Eli Lilly's (LLY) orforglipron and semaglutide, this could be the next major stock catalyst, the firm added.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Structure Therapeutics Inc (GPCR.O) is -20.40, compared to its 5-year average forward P/E of -34.12. For a more detailed relative valuation and DCF analysis to assess Structure Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-34.12
Current PE
-20.40
Overvalued PE
-20.10
Undervalued PE
-48.15

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.77
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.26
Undervalued EV/EBITDA
-7.80

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
5.08
Current PS
0.00
Overvalued PS
15.19
Undervalued PS
-5.03
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

GPCR News & Events

Events Timeline

(ET)
2025-04-17
10:20:09
JPMorgan says Lilly data 'highly favorable' for Structure Therapeutics
select
2025-04-14 (ET)
2025-04-14
09:53:27
JPMorgan says Pfizer news 'mostly a positive' for Structure, Viking
select
2025-04-14
09:47:15
Viking, Structure rally after Pfizer halts obesity drug development
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
11-29TipRanks
Three Stocks Poised for Significant Gains, According to Top Analysts – 11/28/2025

  • Investment Opportunities: Top-rated Wall Street analysts are recommending several stocks as Buys, indicating potential for growth from current levels.

  • Research-Based Picks: These stock selections are backed by solid research, suggesting they have significant upside potential.

  • Explore Further: Investors can click on specific tickers to delve deeper into each company and assess their suitability for investment.

  • Resource Availability: For a comprehensive list of recently rated stocks, TipRanks offers a Daily Stock Ratings & Price Targets tool.

[object Object]
Preview
6.5
11-17Yahoo Finance
BMO Capital Maintains Positive Outlook on Structure Therapeutics (GPCR) Due to Upcoming Trial Results

  • Investment Potential: Structure Therapeutics Inc. (NASDAQ: GPCR) is highlighted as a promising small-cap biotech stock, with BMO Capital maintaining an “Outperform” rating and a $100 price target, driven by anticipated Phase 2b obesity trial results.

  • Financial Performance: In Q3 2025, Structure reported a widened net loss of $65.7 million and high research costs of $59 million, but maintained a strong cash position of $799 million to support ongoing and future studies.

  • Market Position: The company is focused on developing oral small-molecule treatments for metabolic diseases, with its obesity studies on track for completion by year-end.

  • Comparative Analysis: While GPCR shows investment potential, analysts suggest that certain AI stocks may offer better upside potential and lower risk, indicating a competitive investment landscape.

[object Object]
Preview
8.0
11-07NASDAQ.COM
Intriguing GPCR Options for December 2026: Put and Call Opportunities

  • Put Contract Analysis: The $30.00 put contract for GPCR has a bid of $10.50, allowing investors to potentially buy shares at a cost basis of $19.50, which is attractive compared to the current price of $32.26. There is a 76% chance the contract may expire worthless, offering a potential 35% return on cash commitment.

  • Call Contract Strategy: The $37.50 call contract has a bid of $11.50, and if shares are purchased at $32.26 and the call is sold, it could yield a total return of 51.89% if exercised. There is a 30% chance this contract may also expire worthless, allowing the investor to keep both the shares and the premium.

  • Volatility Insights: The implied volatility for the put contract is 119%, while the call contract's implied volatility is 117%. Actual trailing twelve-month volatility is calculated at 73%, indicating a significant difference between implied and actual market conditions.

  • YieldBoost Concept: Both the put and call strategies offer a "YieldBoost," with the put potentially providing a 35% return and the call offering a 35.65% boost if the contracts expire worthless, highlighting the benefits of these options strategies for investors.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Structure Therapeutics Inc (GPCR) stock price today?

The current price of GPCR is 32.85 USD — it has increased 3.89 % in the last trading day.

arrow icon

What is Structure Therapeutics Inc (GPCR)'s business?

Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.

arrow icon

What is the price predicton of GPCR Stock?

Wall Street analysts forecast GPCR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GPCR is 73.38 USD with a low forecast of 50.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Structure Therapeutics Inc (GPCR)'s revenue for the last quarter?

Structure Therapeutics Inc revenue for the last quarter amounts to -73.79M USD, increased 60.98 % YoY.

arrow icon

What is Structure Therapeutics Inc (GPCR)'s earnings per share (EPS) for the last quarter?

Structure Therapeutics Inc. EPS for the last quarter amounts to -52568000.00 USD, increased 157.93 % YoY.

arrow icon

What changes have occurred in the market's expectations for Structure Therapeutics Inc (GPCR)'s fundamentals?

The market is revising Downward the revenue expectations for Structure Therapeutics Inc. (GPCR) for FY2025, with the revenue forecasts being adjusted by -97.04% over the past three months. During the same period, the stock price has changed by 48.78%.
arrow icon

How many employees does Structure Therapeutics Inc (GPCR). have?

Structure Therapeutics Inc (GPCR) has 163 emplpoyees as of December 05 2025.

arrow icon

What is Structure Therapeutics Inc (GPCR) market cap?

Today GPCR has the market capitalization of 1.99B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free